Mapping the S1 and S1' subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
03 2020
Historique:
received: 29 08 2019
accepted: 30 01 2020
entrez: 13 3 2020
pubmed: 13 3 2020
medline: 13 5 2020
Statut: epublish

Résumé

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. A series of 26 new compounds were designed, synthesized, and tested against the recombinant cruzain (Cz) to map its S1/S1´ subsites. The same series was evaluated on a panel of four human cysteine proteases (CatB, CatK, CatL, CatS) and Leishmania mexicana CPB, which is a potential target for the treatment of cutaneous leishmaniasis. The synthesized compounds are dipeptidyl nitriles designed based on the most promising combinations of different moieties in P1 (ten), P2 (six), and P3 (four different building blocks). Eight compounds exhibited a Ki smaller than 20.0 nM for Cz, whereas three compounds met these criteria for LmCPB. Three inhibitors had an EC50 value of ca. 4.0 μM, thus being equipotent to benznidazole according to the antitrypanosomal effects. Our mapping approach and the respective structure-activity relationships provide insights into the specific ligand-target interactions for therapeutically relevant cysteine proteases.

Identifiants

pubmed: 32163418
doi: 10.1371/journal.pntd.0007755
pii: PNTD-D-19-01493
pmc: PMC7067379
doi:

Substances chimiques

Cysteine Proteinase Inhibitors 0
Dipeptides 0
Nitriles 0
Protozoan Proteins 0
Trypanocidal Agents 0
Cysteine Proteases EC 3.4.-
Cysteine Endopeptidases EC 3.4.22.-
cruzipain EC 3.4.22.51

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0007755

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Med Chem. 2019 Oct 24;62(20):9026-9044
pubmed: 31539239
J Exp Med. 1998 Aug 17;188(4):725-34
pubmed: 9705954
Drug Discov Today. 2012 Jan;17(1-2):10-22
pubmed: 21777691
Mol Biochem Parasitol. 2001 Apr 25;114(1):41-52
pubmed: 11356512
Protein Sci. 1997 Aug;6(8):1603-11
pubmed: 9260273
J Mol Biol. 1995 Mar 24;247(2):251-9
pubmed: 7707373
Comput Struct Biotechnol J. 2016 Dec 13;15:86-90
pubmed: 28066532
Trends Pharmacol Sci. 2017 Oct;38(10):873-898
pubmed: 28668224
Bioorg Med Chem. 2019 Jan 1;27(1):1-15
pubmed: 30473362
Chemistry. 2011 Oct 4;17(41):11419-23
pubmed: 21898616
ACS Med Chem Lett. 2015 Dec 28;7(3):211-6
pubmed: 26985300
Bioorg Med Chem Lett. 2009 Aug 1;19(15):4280-3
pubmed: 19515558
Acta Trop. 2010 Jul-Aug;115(1-2):55-68
pubmed: 19900395
J Med Chem. 2000 Sep 7;43(18):3448-52
pubmed: 10978193
Nature. 2010 Jun 24;465(7301):S6-7
pubmed: 20571554
J Chem Inf Model. 2015 Mar 23;55(3):483-94
pubmed: 25760829
Bioorg Med Chem Lett. 2017 Nov 15;27(22):5031-5035
pubmed: 29054358
J Med Chem. 2019 Dec 12;62(23):10497-10525
pubmed: 31361135
Lancet Infect Dis. 2001 Sep;1(2):92-100
pubmed: 11871482
Bioorg Chem. 2018 Sep;79:285-292
pubmed: 29783099
Antimicrob Agents Chemother. 2014;58(2):1167-78
pubmed: 24323474
J Biomol Screen. 2015 Jan;20(1):22-35
pubmed: 25245987
Hum Exp Toxicol. 2006 Aug;25(8):471-9
pubmed: 16937919
Structure. 2000 Aug 15;8(8):831-40
pubmed: 10997902
Bioorg Med Chem. 2019 Nov 15;27(22):115083
pubmed: 31561938
ACS Med Chem Lett. 2014 Aug 11;5(10):1076-81
pubmed: 25313316
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
Chembiochem. 2014 May 5;15(7):955-9
pubmed: 24648212
Adv Exp Med Biol. 2011;712:100-15
pubmed: 21660661
PLoS Negl Trop Dis. 2015 Jul 14;9(7):e0003916
pubmed: 26173110
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7444-9
pubmed: 21041084
J Med Chem. 2015 Aug 27;58(16):6321-35
pubmed: 25915439
Curr Top Med Chem. 2010;10(3):294-322
pubmed: 20166952
Trends Parasitol. 2003 Nov;19(11):495-501
pubmed: 14580960
J Phys Chem A. 2016 Mar 31;120(12):2035-40
pubmed: 26949977

Auteurs

Lorenzo Cianni (L)

Medicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil.
Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
Department of Pharmaceutical/Medicinal Chemistry, Eberhard Karls University Tübingen, Tübingen, Germany.

Carina Lemke (C)

Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.

Erik Gilberg (E)

Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

Christian Feldmann (C)

Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

Fabiana Rosini (F)

Medicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil.

Fernanda Dos Reis Rocho (FDR)

Medicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil.

Jean F R Ribeiro (JFR)

Medicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil.

Daiane Y Tezuka (DY)

Medicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil.
Ribeirão Preto School of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.

Carla D Lopes (CD)

Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo, Brazil.

Sérgio de Albuquerque (S)

Department of Clinical Toxicological and Bromatological Analysis School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, São Paulo, Brazil.

Jürgen Bajorath (J)

Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

Stefan Laufer (S)

Department of Pharmaceutical/Medicinal Chemistry, Eberhard Karls University Tübingen, Tübingen, Germany.

Andrei Leitão (A)

Medicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil.

Michael Gütschow (M)

Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.

Carlos A Montanari (CA)

Medicinal Chemistry Group, Institute of Chemistry of São Carlos, University of São Paulo, São Carlos, São Paulo, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH